Company: PTHS
Filing Date: 2025-05-27
Form Type: DEFM14C
Source: 0001140361-25-020509
Chunk: 504

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-27
Form: DEFM14C
Chunk 504
---
 share and there was an intrinsic value of $0. The Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the three months ended March 31, 2025 and 2024, respectively. RSUs A summary of the status of the Company’s nonvested RSUs as of March 31, 2025, and changes during the three months ended March 31, 2025, is presented below:

| Non-vested RSUs                 |     |    RSUs |     | Weighted- 
   Average 
  Exercise 
     Price |
| Non-vested at December 31, 2024 |     | 292,166 |     |     $1.08 |
| Granted                         |     |       — |     |         — |
| Vested                          |     | -46,345 |     |     -1.10 |
| Forfeited                       |     |       — |     |         — |
| Non-vested at March 31, 2025    |     | 245,821 |     |     $1.07 |

The total number of RSUs granted during the three months ended March 31, 2025 and 2024 was 0 and 0, respectively. The Company recognized stock-based compensation expense related to warrant vesting amortization of $51,910 and $0 for the three months ended March 31, 2025 and 2024, respectively, which is included in general and administrative expenses in the consolidated statements of operations.

F-18

#### TABLE OF CONTENTS

#### NOTE 7 – LEGAL

#### Parexel Claim
On July 31, 2024, the Company received a demand letter from an attorney representing Parexel International (IRL) Limited (“Parexel”). The letter, which was addressed to both the Company and Chromocell Holdings, purports to be a notice of default of a note (the “Promissory Note”) between Chromocell Holdings and Parexel and seeks the payment of allegedly unpaid principal in the amount of $682,551 plus interest exceeding $177,000. The Company denies that it is liable for any of the amounts sought by Parexel; the Company is not a party to the Promissory Note and does not believe it is liable for any amounts allegedly due thereunder. The Company intends to defend itself vigorously in the matter.

#### NOTE 8 – SEGMENT DIS